Abstract
The name technetium was derived by the scientist Mendeleyev from the Greek word technetos, meaning “artificial.” Technetium-99m was discovered in 1937 by Perrier and Segre in a sample of naturally occurring 98Mo irradiated by neutrons and deuterons. The first generator as a source for Tc-99m was introduced in 1957 at the Brookhaven National laboratory, and the first commercially available 99Mo-99mTc generator was made available in 1965. Use of Tc-99m really revolutionized nuclear medicine procedures, particularly with the modern gamma cameras coupled to advanced electronics and computing systems. This revolution was not completed until 1970, when the stannous ion reduction method of 99mTc-diethylenetriaminepentaacetate (DTPA) production as an “instant kit” was described, that simple and convenient “shake-and-bake” preparations for a large number of 99mTc-labeled radiopharmaceuticals were possible.
Keywords
- Human Serum Albumin
- Stannous Chloride
- Reaction Vial
- Ethyl Cysteinate Dime
- Hydroxymethylene Diphosphonate
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Murray IPC, Ell PJ (1998) Nuclear medicine in clinical diagnosis and treatment. Churchill Livingstone, Edinburgh
Dewanjee MK (1990) The chemistry of 99mTc-labeled radiopharmaceuticals. Semin Nucl Med 20:5
Fleming WK, Jay M, Ryo UY (1990) Reconstitution and fractionation of radiopharmaceutical kits. J Nucl Med 31:127–128
Kowalsky RJ, Falen SW (2004) Radiopharmaceuticals in nuclear pharmacy and nuclear medicine, 2nd edn. American Pharmacists Association, Washington
Hung JC, Iverson BC, Toulouse KA, Mahoney DW (2002) Effect of methylene blue stabilizer on in vitro viability and chemotaxis of Tc-99m-exametazime-labeled leukocytes. J Nucl Med 43(7):928–932
Bogsrud TV, Herold TJ, Mahoney DW, Hung JC (1999) Comparison of three cold kit reconstitution techniques for the reduction of hand radiation dose. Nucl Med Commun 20(8):761–767
Zolle I (2007) Technetium-99m pharmaceuticals. Springer, Berlin
Eckelman WC, Steigman J, Paik CH (1996) Radiopharmaceutical chemistry. In: Harpert J, Eckelman WC, Neumann RD (eds) Nuclear medicine: diagnosis and therapy. Thieme Medical, New York, p 213
European Pharmacopoeia (Ph. Eur.) ver. (5.0). Council of Europe, Maisonneuve, Sainte-Ruffine, 2005
Oldendorf WH, Sisson WB, Lisaka Y (1970) Compartmental redistribution of 99mTc-pertechnetate in the presence of perchlorate ion and its relation to plasma protein binding. J Nucl Med 11:85–88
Ahlgren L, Ivarsson S, Johansson L, Mattsson S, Nosslin B (1985) Excretion of radionuclides in human breast milk after administration of radiopharmaceuticals. J Nucl Med 26:1085–1090
Tofe AJ, Bevan JA, Fawzi MB, Francis MD, Silberstein EB, Alexander GA, Gunderson DE, Blair K (1980) Gentisic acid: a new stabilizer for low tin skeletal imaging agents: concise communication. J Nucl Med 21:366–370
Wilson MA (1998) Textbook on nuclear medicine. Lippincott-Raven, Philadelphia
Francis MD, Ferguson DL, Tofe AJ, Bevan JA, Michaels SE (1980) Comparative evaluation of three diphosphonates: in vitro adsorption (C14-labeled) and in vivo osteogenic uptake (Tc-99m complexed). J Nucl Med 21:1185–1189
Fogelman I, Pearson DW, Bessent RG, Tofe AJ, Francis MD (1981) A comparison of skeletal uptakes of three diphosphonates by whole-body retention: concise communication. J Nucl Med 22:880–883
Carlsen JE, Moller MH, Lund JO, Trap-Jensen J (1988) Comparison of four commercial Tc-99m-(Sn)-DTPA preparations used for the measurement of glomerular filtration rate. J Nucl Med 21:126–129
Agnew JE (1991) Characterizing lung aerosol penetration (abstract). J Aerosol Med 4:237–250
de Lange MJ, Piers DA, Kosterink JGW, van Luijk WHJ, Meijer S, de Zeeuw D, Van-der Hem GJ (1989) Renal handling of technetium-99m-DMSA: evidence for glomerular filtration and peri-tubular uptake. J Nucl Med 30:1219–1223
Ramamoorthy N, Shetye SV, Pandey PM, Mani RS, Patel MC, Patel RB, Ramanathan P, Krishna BA, Sharma SM (1987) Preparation and evaluation of 99mTc(V)-DMSA complex: studies in medullary carcinoma of thyroid. Eur J Nucl Med 12:623–628
Murray T, Mckellar K, Owens J, Watson WS, Hilditch TE, Elliott AT (2000) Tc-99m – MAG3: problems with radiochemical purity testing (letter). Nucl Med Commun 21:71–75
Van Hemert FJ, Lenthe H, Schimmel KJM, van Eck-smit BLF (2005) Preparation, radiochemical purity control and stability of Tc-99m mertiatide (Mag-3). Ann Nucl Med 19(4):345–349
Oriuchi N, Miymoto K, Hoshino K, Imai J, Takahashi Y, Sakai S, Shimada A, Endo K (1997) Tc-99m-MAG3: a sensitive indicator for evaluating perfusion and rejection of renal transplants. Nucl Med Commun 18:400–404
Gupta NK, Bomanji JB, Waddington W, Lui D, Costa DC, Verbruggen AM, Ell PJ (1995) Technetium-99m-1,1-ethylenedicysteine scintigraphy in patients with renal disorders. Eur J Nucl Med 22:617–624
Kabasakal L, Turoğlu HT, Onsel C, Ozker K, Uslu I, Atay S, Cansiz T, Sönmezoğlu K, Altiok E, Isitman AT et al (1995) Clinical comparison of technetium-99m-EC, technetium-99m-MAG3 and iodine-131-OIH in renal disorders. J Nucl Med 36:224–228
Jaksic E, Artikoa V, Beatovic S, Djokic D, Jankovic D, Saranovic D, Hana R, Obradovic V (2009) Clinical investigations of 99mTc-p-aminohippuric acid as a new renal agent. Nucl Med Commun 30:76–81
Cooper M, Duston K, Rotureau L (2006) The effect on radiochemical purity of modifications to the method of preparation and dilution of Tc-99m sestamibi. Nucl Med Commun 27:455–460
Varelis P, Parkes SL, Poot MT (1998) The influence of generator eluate on the radiochemical purity of Tc-99m-sestamibi prepared using fractionated Cardiolite® kits. Nucl Med Commun 19(7):615–623
Millar AM, Murray T (2006) Preparation of Tc-99m sestamibi for parathyroid imaging. Nucl Med Commun 27(5):473
Patel M, Owunwanne A, Tuli M, al-Za’abi K, al-Mohannadi S, Sa’ad M, Jahan S, Jacob A, Al-Bunny A (1998) Modified preparation and rapid quality control test for technetium-99m-tetrofosmin. J Nucl Med Technol 26(4):269–273
Graham D, Millar AM (1999) Artifacts in the thin-layer chromatographic analysis of Tc-99m-tetrafosmin Injections. Nucl Med Commun 20:439–444
Ramírez A, Arroyo T, Díaz-Alarcón JP, García-Mendoza A, Muros MA, Martinez del Valle MD, Rodríguez-Fernández A, Acosta-Gómez MJ, Llamas-Elvira JM (2000) An alternative to the reference method for testing the radiochemical purity of Tc-99m-tetrofosmin. Nucl Med Commun 21(2):199–203
Hammes R, Joas LA, Kirschling TE, Ledford JR, Knox TL, Nybo MR et al (2004) A better method of quality control for Tc-99m-tetrafosmin. J Nucl Med Technol 32:72–78
Webber DI, Zimmer AM, Geyer MC, Spies SM (1992) Use of a single-strip chromatography system to assess the lipophilic component in technetium-99m exametazime preparations. J Nucl Med Technol 20:29–32
Solanki C, LI D, Wong A, Barber R, Wraight E, Sampson C (1994) Stabilization and multidose use of exametazime for cerebral perfusion studies. Nucl Med Commun 15(9):718–722
Catafau A (2001) Brain SPECT in clinical practice. Part I: perfusion. J Nucl Med 42:259–271
Pi-lien H, Shu-hua H, Chao-ching H, Song-chei H, Ying-chao C (2008) Tc-99m HMPAO brain SPECT imaging in children with acute cerebellar ataxia. Clin Nucl Med 33(12):841–844
Dormehl IC, Oliver DW, Langen K-J, Hugo N, Croft SA (1997) Technetium-99m-HMPAO, technetium-99m-ECD and iodine-123-IMP cerebral blood flow measurements with pharmacological interventions in primates. J Nucl Med 38:1897–1901
Holman BL, Hellman RS, Goldsmith SJ, Mean IG, Leveille J, Gherardi PG, Moretti JL, Bischof-Dela-loye A, Hill TC, Rigo PM, Van Heertum RL, Ell PJ, Bçll U, DeRoo MC, Morgan RA (1989) Bio-distribution, dosimetry and clinical evaluation of Tc-99m ethyl cysteinate dimer (ECD) in normal subjects and in patients with chronic cerebral infarction. J Nucl Med 30:1018–1024
Myron LL, Anthony RB, John DS (1985) Failure of quality control to detect errors in the preparation of Tc-99m disofenin (DISIDA). Clin Nucl Med 10(7):468–474
Saha GB (2004) Fundamentals of radiopharmacy, 5th edn. Springer, Berlin
Zolle I, Oniciu L, Hofer R (1973) Contribution to the study of the mechanism of labelling human serum albumin (HSA) with technetium-99m. Int J Appl Radiat Isotopes 24:621–626
Strauss HW, Zaret BL, Hurley PJ, Natarajan TK, Pitt P (1971) A scintiphotographic method for measuring left ventricular ejection fraction in man without cardiac catheterization. Am J Cardiol 28:575–580
Chandra R, Shannon J, Braunstein P, Durlov OL (1973) Clinical evaluation of an instant kit for preparation of 99m Tc-MAA for lung scanning. J Nucl Med 14:702–705
Wagner HN, Sabiston DC, Iio M, McAfee JG, Langan JK (1964) Regional pulmonary blood flow in man by radioisotope scanning. JAMA 187:601–603
Zolle I, Rhodes BA, Wagner HN Jr (1970) Preparation of metabolizable radioactive human serum albumin microspheres for studies of the circulation. Int J Appl Radiat Isotopes 21:155–167
Rhodes BA, Stern HS, Buchanan JW, Zolle I, Wagner HN Jr (1971) Lung scanning with Tc-99m-microspheres (abstract). Radiology 99:613–621
Stern HS, McAfee JG, Subramanian G (1966) Preparation, distribution and utilization of technetium-99m-sulfur colloid. J Nucl Med 7:665–675
Ponto JA, Swanson DP, Freitas JE (1987) Clinical manifestations of radiopharmaceutical formulation problems. In: Hladik WB III, Saha GB, Study KT (eds) Essentials of nuclear medicine science. Williams & Wilkins, Baltimore, pp 271–274
Whateley TL, Steele G (1985) Particle size and surface charge studies of a tin colloid radiopharmaceutical for liver scintigraphy. Eur J Nucl Med 19:353–357
Schuind F, Schoutens A, Verhas M, Verschaeren A (1984) Uptake of colloids by bone is dependent on bone blood flow. Eur J Nucl Med 9:461–463
SolcoNanocoll Product monograph of the kit for the preparation of Tc-99m nanocolloid, issued by Sorin Biomedica, Italy (1992)
Alazraki N, Eshima D, Eshima LA, Herda SC, Murray DR, Vansant JP, Taylor AT (1997) Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer and other potential cancers. Semin Nucl Med 27:55–67
Immunomedics Europe product monograph for the CEA-Scan (arcitumomab) kit for the preparation of Tc-99m CEA-Scan. Immunomedics Europe, Darmstadt, Germany (2000)
Moffat FL Jr, Pinsky CM, Hammershaimb L, Petrelli NJ, Patt YZ, Whaley FS, Goldenberg DM (1996) Immunomedics study group clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab’ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. J Clin Oncol 14:2295–2305
Immunomedics Europe product monograph for LeukoScan (sulesomab). Issued by Immunomedics Europe, Darmstadt, Germany (1997)
Gratz S, Schipper ML, Dorner J, Hoffken H, Becker W, Kaiser JW, Behe M, Behr TM (2003) LeukoScan for imaging infection in different clinical settings: a retrospective evaluation and extended review of the literature. Clin Nucl Med 28(4):267–276
Berlex laboratories product monograph for the neotect kit for the preparation of Tc-99m depreotide. Berlex Laboratories, Wayne, NJ (2001) (Diatide, NDA No. 21-012)
Danielsson R, Bââth M, Svensson L, Forslæv U, Kælbeck K-G (2005) Imaging of regional lymph node metastases with 99m Tc-depreotide in patients with lung cancer. Eur J Nucl Med Mol Imaging 32:925–931
Kahn D, Menda Y, Kernstine K, Bushnell DL, McLaughlin K, Miller S, Berbaum K (2004) The utility of 99mTc-depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 125:494–501
Menda Y, Kahn D, Bushnell DL, Thomas M, Miller S, McLaughlin K, Kernstine KH (2001) Nonspecific mediastinal uptake of 99m Tc-depreotide (NeoTect). J Nucl Med 42(Suppl):304P
Blankenberg FG, Katsikis PD, Tait JF et al (1999) Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med 40:184–191
Tait JF, Cerqueira MD, Dewhurst TA (1994) Evaluation of annexin V as platelet directed thrombus targeting agent. Thromb Res 75:491–501
Kemerink D, Liem IN, Hofstra L, Boersma HH, Buijs W, Reutelingsperger C, Heidendal G (2001) Patient dosimetry of intravenously administered 99mTc-annexin V. J Nucl Med 42:382–387
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Saleh, T.B. (2010). Technetium-99m Radiopharmaceuticals. In: Khalil, M. (eds) Basic Sciences of Nuclear Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-85962-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-540-85962-8_3
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-85961-1
Online ISBN: 978-3-540-85962-8
eBook Packages: MedicineMedicine (R0)